Full video transcriptClick to expand
Auto-generated transcript of @buckeye_pmr's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Yeah, I mean, the first question you have to have for the patient is, you know, do you
- 0:04want to save the joint or eventually do you want to replace it?
- 0:08Because if you have arthritis, it's progressive in nature and never gets better on its own,
- 0:13it only gets worse.
- 0:14And that's because of the mechanism of action.
- 0:16If you have arthritis, basically what's happened is either due to overuse trauma or post surgery,
- 0:21your body has released these proteases or little proteins in the joint to clean up damage.
- 0:26But as we get older, we'll say past 30 to 35 years of age, your joints become avascular
- 0:30and these proteins become trapped in the joint.
- 0:33So think of them as termites in there and they start to eat away at the joint and that's
- 0:37the cause of arthritis.
- 0:39And if you don't get rid of the termites, eventually the joint is going to be gone.
- 0:43Now, unfortunately, traditional medicine, the way they treat this is a lot of people do over
- 0:48the counter like NSAIDs.
- 0:49Now, that's like a very common, but the problem with NSAIDs is it does nothing to get rid
- 0:54of the proteases and they work on this pathway called the COX-2 pathway, which actually inhibits
- 0:58cartilage growth.
- 0:59If you have termites in there eating away at your cartilage and you're slowing down cartilage
- 1:05growth, what do you think the NSAIDs are going to do long term?
- 1:07It's actually speed the process up.
- 1:10Another typical medical treatment would be the corticosteroid or steroid injection.
- 1:14But once again, although it's a very potent anti-inflammatory, they also speed up cartilage
- 1:21degradation.
- 1:22That's why you're going to let it get two shots per joint per year because every shock
- 1:25can cause up to 7% bone and mineral loss.
- 1:27So if you get two corticosteroids a year, that's 14% loss on top of the termites eating it.
- 1:33So if you're going that route, you're just saying, I want to replace the joint, which
- 1:36is a choice.
- 1:37But obviously, an artificial joint is never going to be good as what God gave you if you
- 1:42can save your own joint.
- 1:44So a more logical approach for the patient that wants to save the joint and if they haven't
- 1:48gone too far is to do a structured program.
- 1:54And step one is you got to get rid of the termites.
- 1:56And the only way to do that is to use A2M, which is alpha-2 macroglobulin.
- 2:01And basically, that's a product that a physician can make from your own blood.
- 2:04A2M is actually a circulating protein in your bloodstream.
- 2:07It's the largest protein in your venous system.
- 2:10But it's so large, it can't get into your joints.
- 2:13What a physician can do is they can take your blood and filter it down and capture that
- 2:18specific protein, that alpha-2 macroglobulin protein and then use a needle and put it into
- 2:23the joint.
- 2:24And when you put it into the joint, it breaks down the proteins.
- 2:26It's like bug spray gets rid of them.
- 2:29So you get rid of the cause of the arthritis.
- 2:32And then usually what I would do in between time, because there's two parts of this, because
- 2:37we're going to do something to help the tissue go back on the backside.
- 2:40But you have to wait six weeks.
- 2:41You've got to prepare the joint for six weeks.
- 2:43You're going to put the A2M in there with some scaffolding.
- 2:45And it's going to sit there for the next six weeks and just get rid of all the prudases
- 2:49in the joint.
- 2:50Prepare the joint and get it ready for the next step.
- 2:52I would also, in the meantime, use BPC-157 combined with NAD and GHK-Cu.
- 2:58These are all peptides that promote angiogenesis or circulation.
- 3:02They modulate the cytokines, which help get rid of pain.
- 3:04GHK-Cu is also very good for cartilage growth.
- 3:07So that combination vianto for recess, you wear that patch 12 hours a day on the joint
- 3:12and you're treating.
- 3:13So you're bathing that joint with everything in need to get rid of the inflammatory cytokines,
- 3:17the increased circulation there and help grow back cartilage.
- 3:19So very, making it very anabolic.
- 3:23And then after six weeks, I would either do a double spin PRP, not single spin, double
- 3:28spin PRP, or potentially like a warden's jelly, aligraf or exosomes.
- 3:33They all kind of work the same way that's really the provider's preference.
- 3:37But what that does is picture this as kind of the garden analogy.
- 3:40You had termites in your garden, eat your tomatoes for flowers.
- 3:43I don't termites by don't eat flowers.
- 3:44No, probably not.
- 3:45We'll see beetles eating your flowers.
- 3:47So step one is you kill the beetles.
- 3:50Step two is then you basically put the BPC patches with NAD and GHK-Cu is kind of prepare
- 3:55the soil and they kind of till it up a little bit.
- 3:58And then step three is now we're going to put fertilizer in there so they grow back.
- 4:02So that's how that three-pronged approach, the A2M first, BPC, NAD, GHK-Cu to get the soil
- 4:07more ready.
- 4:09And then let's add the fertilizer so things grow back, whether it's warden's jelly extract,
- 4:13exosomes or double spin PRP to help things grow back quicker.
- 4:17That's a true way to fix a joint long term and people ask, well, how long does that last?
- 4:23What should last as long as you last?
- 4:25Because if you're growing back tissue and you got rid of the cause of the arthritis,
- 4:28you're not going to have to go have any more treatments in the future.
BPC-157 and TB-500 peptide claims: what the science actually shows
Quick answer
This video presents a three-component regenerative protocol for osteoarthritis management: autologous A2M injection for protease clearance, transdermal BPC-157/NAD/GHK-Cu patches for angiogenesis and cytokine modulation, and follow-up with PRP, Wharton's jelly, or exosomes for tissue regeneration. While the underlying protease-driven model of osteoarthritis has peer-reviewed support, none of the three specific interventions described has been validated in large randomized controlled trials for this indication. The claim that this protocol produces durable joint preservation that lasts a lifetime is not supported by published long-term outcome data.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
BPC-157 access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 12 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For BPC-157 and TB-500 peptide claims: what the science actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide
Used to frame BPC-157 as an investigational peptide with mixed preclinical and limited human evidence.
PubMed
Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Supports cautious tissue-repair context without presenting BPC-157 as an approved therapy.
PubMed
beta-Thymosins
Background source for thymosin biology and tissue-repair mechanisms.
PubMed
Thymosin beta 4 and the eye: the journey from bench to bedside
Shows how thymosin beta-4 evidence differs by route, tissue, and clinical application.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
BPC-157 should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this bpc-157 video claims cluster
Best for searchers trying to separate BPC-157 research signals from overconfident recovery claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "BPC-157 and TB-500 peptide claims: what the science actually shows" from buckeye_pmr. We read the clip as a Peptide social video fact-checks claim about BPC-157, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video presents a three-component regenerative protocol for osteoarthritis management: autologous A2M injection for protease clearance, transdermal BPC-157/NAD/GHK-Cu patches for angiogenesis and cytokine modulation, and follow-up with PRP, Wharton's jelly, or exosomes for tissue regeneration.
The reason this review is not generic is the source wording and the canonical claim label "peptides tiktok 7532966375430704439." In this clip, the useful excerpt is: "Yeah, I mean, the first question you have to have for the patient is, you know, do you want to save the joint or eventually do you want to replace it?" That wording changes the review because it points to BPC-157 safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Multifunctionality and Possible Medical Application of the BPC 157 Peptide (2025), Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing (2019), and Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025), plus the creator's own wording. BPC-157 still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
This video presents a three-component regenerative protocol for osteoarthritis management: autologous A2M injection for protease clearance, transdermal BPC-157/NAD/GHK-Cu patches for angiogenesis and cytokine modulation, and follow-up with PRP, Wharton's jelly, or exosomes for tissue regeneration.
FormBlends verdict
BPC-157 safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the BPC-157 guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video presents a three-component regenerative protocol for osteoarthritis management: autologous A2M injection for protease clearance, transdermal BPC-157/NAD/GHK-Cu patches for angiogenesis and cytokine modulation, and follow-up with PRP, Wharton's jelly, or exosomes for tissue regeneration. While the underlying protease-driven model of osteoarthritis has peer-reviewed support, none of the three specific interventions described has been validated in large randomized controlled trials for this indication. The claim that this protocol produces durable joint preservation that lasts a lifetime is not supported by published long-term outcome data.
- A2M (alpha-2 macroglobulin) has shown protease inhibition in vitro and in small case series, but no large randomized controlled trial has confirmed it stops osteoarthritis progression in humans.
- McAlindon et al. (2017, JAMA) found that repeated intra-articular triamcinolone over two years was associated with significantly greater cartilage volume loss compared to placebo, supporting caution with corticosteroids but not the specific 7% per-injection figure cited.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- BPC-157 decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the BPC-157 guide, cost path, safety notes, and provider review before acting.
Review BPC-157What You'll Learn
- A2M (alpha-2 macroglobulin) has shown protease inhibition in vitro and in small case series, but no large randomized controlled trial has confirmed it stops osteoarthritis progression in humans.
- McAlindon et al. (2017, JAMA) found that repeated intra-articular triamcinolone over two years was associated with significantly greater cartilage volume loss compared to placebo, supporting caution with corticosteroids but not the specific 7% per-injection figure cited.
- BPC-157 has no completed human clinical trials for osteoarthritis or intra-articular use. All healing data in the literature comes from rodent models.
- Transdermal delivery of peptides like BPC-157 and GHK-Cu to joint tissue has not been validated in human pharmacokinetic studies. The patch mechanism relies on theoretical absorption, not measured intra-articular concentration data.
- Wharton's jelly, exosomes, and PRP are not interchangeable. Each has a distinct cell biology and regulatory status. Exosome products in particular face significant FDA regulatory uncertainty in the US as of 2024.
- The protease-driven model of osteoarthritis is legitimate science, but osteoarthritis is a multifactorial disease involving mechanical, inflammatory, and metabolic pathways. No single mechanism explains all cases.
- Patients considering regenerative arthritis treatments should request peer-reviewed outcome data specific to their procedure, not just mechanistic explanations, and should consult both a rheumatologist and a regenerative medicine specialist before committing to out-of-pocket protocols.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @buckeye_pmr actually say?
A physician on TikTok laid out a three-step protocol for treating osteoarthritis without joint replacement. Step one: inject alpha-2 macroglobulin (A2M) derived from your own blood to "get rid of the termites" he says are destroying cartilage. Step two: wear transdermal patches containing BPC-157, NAD, and GHK-Cu for six weeks to prep the joint. Step three: follow up with double-spin PRP, Wharton's jelly, or exosomes as a regenerative "fertilizer." He also claims NSAIDs "speed up" arthritis by inhibiting cartilage growth, and that each corticosteroid injection causes "up to 7% bone and mineral loss."
This is a complex, multi-part pitch. Some pieces have legitimate scientific backing. Others are speculative, overstated, or simply not supported by the evidence he implies exists. The framing as a definitive fix that "should last as long as you last" deserves real scrutiny.
Does the science back this up?
Partially, and with important caveats. The protease-driven model of osteoarthritis is real, but it is a significant oversimplification. A2M does show early promise as an intra-articular treatment, but the evidence base is thin. The peptide patch claims are the weakest link scientifically.
The protease hypothesis has support: matrix metalloproteinases (MMPs) and other degradative enzymes do contribute to cartilage breakdown in osteoarthritis (Goldring and Goldring, 2010, Arthritis Research and Therapy). A2M has been studied as a protease inhibitor in synovial fluid. Moser et al. (2018, Journal of Orthopaedic Research) found A2M reduced MMP activity in vitro, and small clinical series suggest symptom improvement, but there are no large randomized controlled trials confirming the "get rid of the cause" framing he uses.
BPC-157 has shown tendon and soft tissue healing effects in rodent models (Sikiric et al., 2018, Current Pharmaceutical Design), but there are zero published human clinical trials on intra-articular or transdermal BPC-157 for osteoarthritis. GHK-Cu has demonstrated some pro-collagen signaling in cell studies (Pickart et al., 2015, Journal of Aging Science), but again, transdermal delivery to a joint specifically has not been validated in clinical trials.
What did they get wrong (or right)?
The NSAID claim deserves a closer look. He says NSAIDs "inhibit cartilage growth" via COX-2 inhibition and therefore accelerate joint destruction. This is not a fringe idea. There is real evidence that COX-2 inhibition can impair chondrocyte function and some observational data linking long-term NSAID use to accelerated radiographic joint space narrowing (Helin-Salmivaara et al., 2006, Annals of the Rheumatic Diseases). Calling them definitively cartilage-destroying is an overstatement, but the concern is scientifically grounded.
The corticosteroid "7% bone and mineral loss per injection" claim is where things get shaky. Intra-articular corticosteroids are associated with local tissue effects and some systemic absorption, but the specific 7% per-injection figure appears to lack a clear published source. McAlindon et al. (2017, JAMA) did find accelerated cartilage volume loss with repeated intra-articular triamcinolone, which supports caution, but the precise quantification he cites is not traceable to peer-reviewed literature.
He correctly identifies that Wharton's jelly, exosomes, and PRP have overlapping mechanisms, though calling them interchangeable is an oversimplification that most regenerative medicine researchers would push back on.
What should you actually know?
The regenerative medicine space he is operating in is real medicine being actively researched, but it is not settled medicine. The A2M procedure is offered by a growing number of clinics, but it is not FDA-approved as a specific arthritis treatment, and out-of-pocket costs are substantial with no insurance coverage. Patients should ask for informed consent documentation that includes the current state of the evidence, not just a mechanistic pitch.
Transdermal peptide patches are the most speculative part of this protocol. Skin is an excellent barrier, and the evidence that BPC-157 or GHK-Cu penetrates to joint tissue via a topical patch at therapeutic concentrations does not exist in the published human literature. That does not mean the components have no biological activity, but it does mean the delivery claim is being carried by logic and cell-culture data, not clinical proof.
Anyone considering this approach should have a frank conversation with a board-certified orthopedic surgeon or rheumatologist alongside a regenerative medicine provider. The idea of preserving a joint rather than replacing it is a reasonable goal shared by mainstream medicine. The specific protocol described here goes well beyond what current evidence can confirm.
Bottom line
This creator is a physician presenting a mechanistically coherent but evidence-light protocol. The underlying biology is not invented. The extrapolation from that biology to a specific multi-step commercial protocol is where the gap between hypothesis and proof opens up. Patients with osteoarthritis deserve to know the difference.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
buckeye_pmr · TikTok creator
49.4K views on this video
BPC-157 and TB-500 peptide claims: what the science actually shows
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about a2m (alpha-2 macroglobulin) has shown protease inhibition in vitro?
A2M (alpha-2 macroglobulin) has shown protease inhibition in vitro and in small case series, but no large randomized controlled trial has confirmed it stops osteoarthritis progression in humans.
What does the video say about mcalindon et al. (2017, jama) found?
McAlindon et al. (2017, JAMA) found that repeated intra-articular triamcinolone over two years was associated with significantly greater cartilage volume loss compared to placebo, supporting caution with corticosteroids but not the specific 7% per-injection figure cited.
What does the video say about bpc-157 has no completed human clinical trials for osteoarthritis?
BPC-157 has no completed human clinical trials for osteoarthritis or intra-articular use. All healing data in the literature comes from rodent models.
What does the video say about transdermal delivery of peptides like bpc-157?
Transdermal delivery of peptides like BPC-157 and GHK-Cu to joint tissue has not been validated in human pharmacokinetic studies. The patch mechanism relies on theoretical absorption, not measured intra-articular concentration data.
What does the video say about wharton's jelly, exosomes,?
Wharton's jelly, exosomes, and PRP are not interchangeable. Each has a distinct cell biology and regulatory status. Exosome products in particular face significant FDA regulatory uncertainty in the US as of 2024.
What does the video say about the protease-driven model of osteoarthritis?
The protease-driven model of osteoarthritis is legitimate science, but osteoarthritis is a multifactorial disease involving mechanical, inflammatory, and metabolic pathways. No single mechanism explains all cases.
Sources & references
- [1]Moser et al. (2018)
- [2]Sikiric et al., 2018
- [3]Pickart et al., 2015
- [4]Helin-Salmivaara et al., 2006
- [5]McAlindon et al. (2017)
- [6]Goldring and Goldring, 2010
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by buckeye_pmr, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.